AlphAIAlphAI — Financial news for AI agents
insidermonkey.comSEP 282 min read$COO

Is Jana Partners Right that Cooper (COO) Needs a Different Kind of Leadership?

Jana Partners is pressuring The Cooper Companies (COO) to replace its CEO and board chair, and explore selling its CooperVision and CooperSurgical businesses, citing a 28% stock decline and operational issues. COO reported Q3 revenue of $1.07B, non-GAAP earnings up 4%, and free cash flow up 66% to $273M. Jana argues for leadership changes and potential asset sales, while critics point to flat revenue and inventory pressures.

Original reporting
insidermonkey.com
Published Sep 28, 2026, 1:49 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Is Jana Partners Right that Cooper (COO) Needs a Different Kind of Leadership? — source image
Source · insidermonkey.com
Decision brief

The 30-second read

$COOBearishLow
01

Why it matters

The proxy fight and possible asset sales introduce execution risk, but also a catalyst for strategic review that could reshape the company's valuation.

02

Market read

COO's stock may experience volatility as the proxy contest approaches, with investors weighing governance risk against potential value‑unlocking transactions.

03

What to watch

Potential for a well‑priced asset sale could offset governance concerns and support the share price.

Relevance 6/10Novelty 5/10Timing: ahead of the January proxy‑fight deadline

Background

Activist Jana Partners, holding a stake since 2025, is urging The Cooper Companies to overhaul its leadership and consider divesting parts of its business amid a 28% share decline.

Company-level read

Ticker impact

$COOBearishHigh confidence
Context

Jana Partners is pressuring The Cooper Companies (COO) to replace its CEO and board chair and threatens a proxy fight ahead of a January nomination deadline.

Expected impact

likely downside as the market prices in governance risk and possible leadership turnover.

Evidence & confidence

Activist pressure and a looming proxy contest historically depress stock prices, especially when tied to operational concerns.

Market effects

Sector

Eye‑care and medical‑device sector may see heightened scrutiny of governance practices.

Regional

U.S. market participants focused on COO; limited broader regional effect.

Global

Limited to investors tracking activist activity in U.S. healthcare companies.

Counterpoint

What could challenge this read

If Jana Partners fails to secure board influence, the leadership change could unlock value and the stock may rally on a successful turnaround.

Key entities

  • Activist Investor
    Jana Partners

    Pressuring COO for leadership change and asset sales.

  • Company
    The Cooper Companies, Inc.

    Contact‑lens and medical‑device maker facing activist pressure.

Read at source← All news

Related articles

SEP 21
$COOMedAI 8/10

A Failed Auction and a 15% Drop: Is Cooper Companies (COO) a Value Trap or a Bargain?

Cooper Companies (COO) ended its 9-month effort to sell CooperSurgical after bids undervalued the business, according to management. The stock dropped 15% to a 52-week low near $51 after a Q3 miss and cut outlook. The company's core contact lens business, CooperVision, posted flat organic revenue growth, contributing to the guidance cut. Management authorized a $1B share repurchase program, while Bank of America questioned the valuation. COO reported record Q3 free cash flow of $273M.

insidermonkey.com2 min
SEP 14
$COOMedAI 8/10

The Cooper Companies (COO) Faces Near-Term Pressure from Slowing Contact Lens Demand

The Cooper Companies (COO) lowered its fiscal 2026 profit and revenue forecasts due to weaker-than-expected contact lens demand, with adjusted EPS now expected at $4.51–$4.55 and revenue at $4.23–$4.25 billion. Q3 revenue was $1.07 billion, missing estimates, though adjusted EPS beat at $1.15. The company cited U.S. channel inventory reductions as a key factor and decided to retain CooperSurgical.

finance.yahoo.com3 min
SEP 11
$COOMedAI 8/10

Cooper Companies (COO) Bets on Fertility Growth Despite Weakness in CooperVision

Cooper Companies (COO) reported Q3 FY2026 revenue of $1.066B, up 1%, and adjusted EPS of $1.15, up 4%. The company spent $339.1M on share buybacks and has $1.5B remaining in repurchase capacity. Fertility segment growth and strong cash flow offset weakness in CooperVision, which saw flat organic growth and revenue declines in Americas and Asia Pacific. Gross margin improved to 67% on a GAAP basis, while adjusted operating margin rose 30 basis points to 26%.

yahoo.com2 min
SEP 11
$COOMed

Why Cooper, Freeport-McMoRan, and Baker Hughes Plunged

Cooper Companies (COO) fell 14.67% after reporting Q3 revenue of $1.07B and Q4 guidance below estimates. Freeport-McMoRan (FCX) dropped 6.59% due to White House uncertainty on copper tariffs. Baker Hughes (BKR) declined 6.66% despite raising its full-year revenue guidance to $28.5B-$30.3B.

baystreet.ca2 min